drugset / Trial / NCT00863863

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

NCT00863863

Phase 1 Completed 40 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the rate and extent of absorption of griseofulvin from a test formulation of Griseofulvin 125 mg/5 mL Suspension versus the reference Grifulvin V® 125 mg/5 mL Suspension under fed conditions.

Timeline

Start
2006-01
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Griseofulvin Small molecule 125 mg

Indications

No indication recorded.